Printer Friendly

IDEC PHARMACEUTICALS AND SMITHKLINE BEECHAM EXPAND 'PRIMATIZED' ANTIBODY COLLABORATION TO INCLUDE ASIA

 IDEC Will Receive Up to $20 Million in Additional Payments,
 Bringing Total Potential Payments to Approximately $50 Million,
 Plus Product Royalties and Equity Investment
 LA JOLLA and MOUNTAIN VIEW, Calif., Feb. 22 /PRNewswire/ -- IDEC Pharmaceuticals Corporation (NASDAQ: IDPH) and SmithKline Beecham (NYSE: SBE) have expanded their previously announced collaborative development agreement to include granting SmithKline Beecham rights in Japan and other Asian territories. This is a significant expansion of their agreement aimed at the commercialization of therapeutic products based on "primatized" anti-CD4 antibodies.
 Under the terms of the amended agreement, IDEC Pharmaceuticals will receive up to $20 million in additional payments, bringing the total potential milestone payments to approximately $50 million.
 IDEC and SmithKline Beecham share co-promotion rights in the United States and Canada. SmithKline Beecham now has exclusive rights in the rest of the world. IDEC will receive royalties on sales of products which may be commercialized as a result of this collaboration.
 The primatized antibodies central to the collaborative agreement are part of a new class of therapeutic antibodies developed by IDEC Pharmaceuticals. Differing significantly from other types of antibodies, primatized antibodies are a genetically engineered combination of macaque monkey antibodies and human antibodies. The antibodies are manufactured using mammalian cell-culture techniques. They contain no mouse components whatsoever. Furthermore, they offer potential for treating a variety of chronic autoimmune diseases that are currently not treatable with existing antibody-based therapies.
 "The objective of our collaboration with SmithKline Beecham is to develop and commercialize primatized anti-CD4 antibodies to treat chronic diseases that require long-term therapy," said William H. Rastetter, Ph.D., president and chief executive officer of IDEC Pharmaceuticals. "Our initial focus is on the treatment of rheumatoid arthritis. Potential future applications of the anti-CD4 antibody include the treatment of systemic lupus erythematosus, psoriasis, inflammatory bowel disease and multiple sclerosis."
 During the product development phase, IDEC Pharmaceuticals will be responsible for preclinical development, initial supplies of clinical-grade antibody and early human clinical studies. SmithKline Beecham will carry our later stage development efforts, enabling both companies to exploit SmithKline Beecham's extensive, well established infrastructure to advance development candidates as rapidly as possible through costly, large-scale human clinical studies and the subsequent regulatory approval process.
 SmithKline Beecham -- one of the world's leading healthcare companies -- discovers, develops, manufactures and markets human and animal pharmaceuticals, over-the-counter medicines and clinical laboratory testing services.
 IDEC Pharmaceuticals is focused on the development of antibody- based therapies for the treatment of a wide range of human diseases. These agents typically are designed to act through immune system mechanisms and potentially offer greater specificity of action, longer therapeutic effect and lower toxicity than is typical of existing therapies. Moreover, the company's product candidates potentially can be administered in outpatient settings, helping to reduce overall treatment costs. Several human clinical studies are in progress using product candidates for the treatment of B-cell lymphomas, malignant melanoma and HIV infection. Late-stage preclinical testing of an anti-CD4 antibody is under way for the treatment of autoimmune diseases, as part of the company's product- development collaboration with SmithKline Beecham. Separate from this collaboration, IDEC Pharmaceuticals is developing additional primatized antibodies for a variety of therapeutic applications.
 IDEC Pharmaceuticals is headquartered at 11099 North Torrey Pines Road, La Jolla, CA 92037. Company operations also are located in Mountain View, CA.
 /EDITOR'S NOTE: 1) For further information on the agreement between IDEC Pharmaceuticals and SmithKline Beecham, see Oct. 14, 1992, press release entitled "IDEC Pharmaceuticals and SmithKline Beecham Announce Collaboration to Develop and Commercialize Primatized' Antibodies for Arthritis." 2) IDEC Pharmaceuticals has issued two additional press releases today entitled: "IDEC Pharmaceuticals Significantly Expands Lymphoma Clinical Program" and "IDEC Pharmaceuticals Starting to Unify Facilities and Staff in San Diego."/
 -0- 2/22/93
 /CONTACT: Richard W. Krawiec, director, investor relations and corporate communications, 619-458-0600, or Clifford Orent, senior VP & COO, 415-940-1200/
 (IDPH SBE)


CO: IDEC Pharmaceuticals Corp.; SmithKline Beecham ST: California IN: MTC SU:

JB-JL -- SD003 -- 8819 02/22/93 09:06 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 22, 1993
Words:656
Previous Article:AREA ENVIRONMENTAL EXECUTIVE AND U.S. SENATOR TO SPEAK FRIDAY AT WATER POLICY BRIEFING
Next Article:IDEC PHARMACEUTICALS SIGNIFICANTLY EXPANDS LYMPHOMA CLINICAL PROGRAM
Topics:


Related Articles
CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
IDEC PHARMACEUTICALS AND SMITHKLINE BEECHAM ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE 'PRIMATIZED' ANTIBODIES FOR ARTHRITIS
IDEC PHARMACEUTICALS STARTING TO UNIFY FACILITIES AND STAFF IN SAN DIEGO
IDEC PHARMACEUTICALS SIGNIFICANTLY EXPANDS LYMPHOMA CLINICAL PROGRAM
IDEC PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR-END 1992 RESULTS
IDEC PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
IDEC PHARMACEUTICALS RECEIVES FDA CLEARANCE TO BEGIN HUMAN TESTING OF PRIMATIZED(TM) ANTIBODY FOR RHEUMATOID ARTHRITIS
IDEC PHARMACEUTICALS REPORTS THIRD QUARTER 1993 RESULTS
GENENTECH LICENSES IDEC PHARMACEUTICALS' TECHNOLOGY FOR HIGH-LEVEL GENE EXPRESSION
IDEC Pharmaceuticals Announces Phase II Trial of PRIMATIZED Monoclonal Antibody Appears to be Safe and Effective in Treatment of Rheumatoid Arthritis

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters